Literature DB >> 207064

Plasma glucagon in insulinoma.

A Ohneda, K Matsuda, K Horigome, S Ishii, A Yanbe, Y Maruhama.   

Abstract

Nine patients with insulinoma were studied in order to investigate glucagon levels in the fasting state and the response of plasma glucagon to tolbutamide and arginine. Fasting plasma glucagon levels were within the normal range in all patients except two cases with malignant insulinoma. Although there was no correlation between blood glucose and plasma glucagon, a significant correlation between plasma glucagon and plasma insulin was observed. No detectable changes were found in glucagon levels during tolbutamide injection. In almost all patients except one an exaggerated response of plasma glucagon was demonstrated during arginine infusion test.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 207064     DOI: 10.1007/bf02580970

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  22 in total

1.  Production of glucagon antibodies and their role in metabolism and immunoassay of glucagon.

Authors:  G M GRODSKY; T HAYASHIDA; C T PENG; I I GESCHWIND
Journal:  Proc Soc Exp Biol Med       Date:  1961-07

2.  Immunoassay of insulin using a two-antibody system.

Authors:  C R MORGAN; A LAZAROW
Journal:  Proc Soc Exp Biol Med       Date:  1962-05

3.  Insulin response to tolbutamide-glucose load in normal and diabetic subjects.

Authors:  A Oneda; M Sato; S Yamagata
Journal:  Tohoku J Exp Med       Date:  1974-10       Impact factor: 1.848

4.  Suppression of pancreatic glucagon release by the hypoglycaemic sulphonylureas.

Authors:  E Samols; J M Tyler; P Mialhe
Journal:  Lancet       Date:  1969-01-25       Impact factor: 79.321

5.  Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin.

Authors:  I M Murray-Lyon; A L Eddleston; R Williams; M Brown; B M Hogbin; A Bennett; J C Edwards; K W Taylor
Journal:  Lancet       Date:  1968-10-26       Impact factor: 79.321

6.  Acute suppression of insulin and glucose levels by synthetic somatostatin in normal human subjects.

Authors:  G W DeVane; T M Siler; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1974-05       Impact factor: 5.958

7.  Characterization of the glucagon response to hypoglycemia in man.

Authors:  J E Gerich; V Schneider; S E Dippe; M Langlois; C Noacco; J H Karam; P H Forsham
Journal:  J Clin Endocrinol Metab       Date:  1974-01       Impact factor: 5.958

8.  Failure of sulfonylureas to suppress plasma glucagon in man.

Authors:  S Pek; S S Fajans; J C Floyd; R F Knopf; J W Conn
Journal:  Diabetes       Date:  1972-04       Impact factor: 9.461

9.  Glucagon response to arginine after treatment of diabetes mellitus.

Authors:  A Ohneda; S Ishii; K Horigome; S Yamagata
Journal:  Diabetes       Date:  1975-09       Impact factor: 9.461

10.  Evidence for a physiologic role of pancreatic glucagon in human glucose homeostasis: studies with somatostatin.

Authors:  J E Gerich; M Lorenzi; S Hane; G Gustafson; R Guillemin; P H Forsham
Journal:  Metabolism       Date:  1975-02       Impact factor: 8.694

View more
  1 in total

1.  Evidence for a therapeutic effect of dl-propranolol in benign and malignant insulinoma: report of three cases.

Authors:  I Blum; Y Rusecki; M Doron; M Lahav; Z Laron; A Atsmon
Journal:  J Endocrinol Invest       Date:  1983-02       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.